Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Skin Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Skin Neoplasm

Cancer Family

Skin Neoplasm

CI-CAN-00000051Explore in graph →

Non-malignant346 active trials14 approved drugs74 evidence items

NCIt: C3372
MeSH: D012878

Overview
Statistics
Survival
Genomics19
Variants & evidence74
Drugs32
Trials1424
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (99)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 99 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Mutational landscape of aggressive cutaneous squamous cell carcinoma.
· Clin Cancer Res · 2014 · PMID 25303977 · validated cbioportal_study pubmed
Targeting mutant NRAS signaling pathways in melanoma.
· Pharmacol Res · 2016 · PMID 26987942 · validated civic_curation pubmed
Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans.
· Mod Pathol · 2007 · PMID 17431412 · validated civic_curation pubmed
Genomic alterations of dermatofibrosarcoma protuberans revealed by whole-genome sequencing.
· Br J Dermatol · 2022 · PMID 35441365 · validated civic_curation pubmed
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
· Eur J Cancer · 2015 · PMID 25542057 · validated civic_curation pubmed
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
· Lancet Oncol · 2013 · PMID 23414587 · validated civic_curation pubmed
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
· Lancet Oncol · 2012 · PMID 22805292 · validated civic_curation pubmed

Showing 51–75 of 99 publications

← Previous
1
2
3
4
Next →

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.

· Clin Cancer Res · 2016 · PMID 26307133 · validated civic_curation pubmed

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

· Cancer Discov · 2013 · PMID 23288408 · validated civic_curation pubmed

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

· N Engl J Med · 2016 · PMID 27433843 · validated civic_curation pubmed

Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.

· Nature · 2015 · PMID 26444240 · validated civic_curation pubmed

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.

· J Clin Oncol · 2016 · PMID 24934779 · validated civic_curation pubmed

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

· Cancer Discov · 2012 · PMID 22798288 · validated civic_curation pubmed

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

· Melanoma Res · 2014 · PMID 24933606 · validated civic_curation pubmed

A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure.

· Onco Targets Ther · 2018 · PMID 29760553 · validated civic_curation pubmed

COL1A1-PDGFB fusion in a pediatric Bednar tumor with 2 copies of a der(22)t(17;22).

· Cancer Genet Cytogenet · 2006 · PMID 16843106 · validated civic_curation pubmed

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.

· Oncologist · 2025 · PMID 39504576 · validated civic_curation pubmed

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.

· Oncologist · 2024 · PMID 38470950 · validated civic_curation pubmed

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

· J Clin Oncol · 2008 · PMID 18390968 · validated civic_curation pubmed

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

· Ann Oncol · 2014 · PMID 24504448 · validated civic_curation pubmed

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

· Pigment Cell Melanoma Res · 2015 · PMID 26072686 · validated civic_curation pubmed

Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

· Case Rep Oncol Med · 2015 · PMID 25692060 · validated civic_curation pubmed

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

· N Engl J Med · 2012 · PMID 22256804 · validated civic_curation pubmed

A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel NTRK3-SCAPER gene fusion.

· J Cutan Pathol · 2020 · PMID 31437301 · validated civic_curation pubmed

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

· Cancer Discov · 2014 · PMID 24265153 · validated cbioportal_study pubmed